Developments in transgenic technology have greatly enhanced our ability to understand the functions of various genes in animal models and relevant human diseases. The tetracycline (tet)-regulated transactivation system for inducing gene expression allowed us to control the expression of exogenous genes in a temporal and quantitative way. The ability to manipulate a cell-specific promoter enabled us to express one particular protein in a single type of cell. The combination of a tetracycline system and a tissue-specific promoter has led us to the development of an innovative gene expression system, which is able to express genes in a cell type-specific and time-and level-controllable fashion. An oligodendrocyte-specific myelin basic protein (MBP) gene promoter controls the reversed tet-inducible transactivator. The green fluorescent protein (GFP) gene was placed under the control of the human cytomegalovirus (CMV) basic promoter in tandem with seven tet-responsive elements (TRE), binding sites for the activated transactivator. Upon the addition of doxycycline (DOX, a tetracycline derivative), tet transactivators became activated and bound to one or more TRE, leading to the activation of the CMV promoter and the expression of GFP in oligodendrocytes. We have successfully expressed GFP and luciferase at high levels in oligodendrocytes in a timeand dose-dependent fashion. In the absence of DOX, there was almost no GFP expression in oligodendroglial cultures. Graded levels of GFP expression were observed after induction with DOX (0.5 to 12.5 jig/ml). Our data indicate that this inducible gene expression system is useful for the study of gene function in vivo and for the development of transgenic animal models relevant to human diseases such as multiple sclerosis.
Introduction
Conventional transgenic technology has contributed significantly to the understanding of the functions of genes within the context of living organisms. However, traditional transgenic technology is limited by the fact that transgenes are overexpressed in multiple tissues from conception onward (1) . This is particularly problematic in the development of the nervous systems such as the myelin sheath, where changes in the level of one gene induce compensatory changes throughout the system (2) . The newest challenge to the transgenic technology is to have the abili4y to regulate the expression of a transgene in terms of level, anatomical location, and time (3) .
The recent development of a tetracycline (tet)-regulated transactivation system for inducible gene expression makes quantitative, spatial, and temporal induction of transgenes in cells and animals possible (4) (5) (6) . In the tet system, inducibility of transgene expression is conferred by the transactivator, a reverse-tetracycline repressor/ VP16 (rTetR/VP16) fusion protein, which undergoes a conformational change and binds the tetresponsive element (TRE) (Fig. 1) , was verified by restriction endonuclease mapping. As a comparison, the GFP gene was replaced by luciferase to create a pTetra-MBP-LUC construct. The pE-GFP-N2 construct contains a CMV promoter to control GFP expression (Clontech). An Endofree Plasmid Giga preparation kit (Qiagen, Valencia, CA) was used to obtain pure plasmid DNA for transfection. The correct orientation and sequences of all DNA constructs were confirmed by using a di-deoxy chain-termination sequencing method.
Electroporation
Transfection of human oligodendroglioma cells [HOG, (8) ], primary rat oligodendrocytes, and astrocytes with pTetra-MBP-GFP, pTetra-MBP-LUC, and pE-GFP-N2 constructs was performed using electroporation. Briefly, oligodendrocytes were harvested by trypsinization. The cells were resuspended at 1 X 106 cells/ml in serum-free Dulbecco's modified Eagle's medium (DMEM). A 700-,ul aliquot of cell suspension was placed in a 4- The expression level of the reporter gene, as reflected by the amounts of luciferase activity, was highly correlated (p < 0.01) to the levels of DOX added to the culture medium (Fig. 2) . Since the product of the luciferase reporter gene and the assay did not identify the source of luciferase-secreting cells, we used GFP as a reporter gene to directly visualize the cells that express GFP and determine its intensity as a function of promoter activity. As shown in Figure 3 , the intensity of green fluorescence was highly correlated with the concentration of DOX added into the culture medium. These GFP data are in agreement with the luciferase data that show that the inducible gene expression system is working well in vitro.
After we optimized the conditions of transfection, rat primary oligodendroglial cultures were transfected with pTetra-MBP-GFP DNA construct (Fig. 1) . A small number of GFP+ cells were observed in the absence of DOX (Fig. 4) . With increasing concentrations of DOX, the GFP+ cells became more abundant and reached about 38% GFP expression of the total population (Fig. 3) Figure 1 , using the MBP promoter and luciferase as a reporter gene. Forty-eight hours later, DOX was added at the indicated concentrations and incubated for 24 hr, after which luciferase activity and protein 10 hr after addition of DOX (10.0 ,tg/ml). These cells remained positive for as long as 1 week, which reflected the long half-life and stability of GFP (12) . To demonstrate that GFP was specifically expressed, we transfected pTetra-MBP-GFP DNA construct into mixed glial cultures (containing astrocyte, oligodendrocytes, and microglia) and pure astrocytes. We observed that only oligodendrocytes were GFP+ by morphological criteria (Fig. 4M) Figure 6 , the maximal expression of GFP occurred at 66 hr after transfection of HOG cells. Compared to the MBP promoter, the CMV promoter was stronger in the activation of GFP expression in HOG cells. Furthermore, CMVdriven construct expressed GFP earlier than the MBP-driven construct, since the latter construct needs two transcriptions and two translations to express GFP. In the interval of 66 to 90 hr, GFP expression in CMV-GFP and MBP-GFP constructs dropped by 10% and 5%, respectively.
The GFP fluorescence from pTetra-MBP-GFP disappeared after 1 week, but GFP+ cells were still present in relatively high number in the pCMV-GFP transfected cells even after 3 weeks (data not shown).
Discussion
We have successfully expressed GFP and luciferase at high levels in oligodendrocytes cells in a time-and DOX-dose-dependent fashion. Reporter expression was restricted to oligodendrocytes (Fig. 4) (7, 11, 14, 15 (4) . The levels of luciferase activity induced by DOX in our experiment were much lower compared with the results reported by others (4) (5) (6) 16 ). The discrepancy is probably due to variability in experimental design or protocols, such as background subtraction when processing the raw data. The second possible reason for deviation may be due to the different times of measurement to which the luminometer was set. The value of relative luciferase activity increases with duration of measurement set on the luminometer. In contrast, GFP acts to shift the colors of bioluminescence from blue to green and does not have an amplifying effect. Therefore, the fold induction is smaller and requires a high dose of the inducer, DOX (Fig. 3) . Figure 5 illustrates the use of GFP as a reporter gene for the study of real time kinetics with an inducible expression system. There was an unexpected and relatively high level (11 %) of background due to GFP expression from the pTetra-MBP-GFP construct in the absence of DOX. This can be explained as the result of leaky expression of DNA construct per se and/or due to the nonintegrated effect in a transient transfection system. The stable transfer of tet-regulated system into a cell line or integrated into a locus may reduce the problem (17) (18) (19) . The leaky expression of GFP in the study may be related to the fact that we put the system of cell-specific expression of rTetR/VP16 and the system of tetresponsive promoter with the reporter gene into a single vector system. Most researchers use two separated systems, which have advantages such as flexability to link a gene of interest and tight controlled expression. In mature oligodendrocytes, a 1.4-kb MBP gene promoter is relatively strong in terms of transactivating downstream gene expression (7, 11, 17) . Therefore, relatively high levels of reversed tet-transactivators were accumulated and sequestered within the cytoplasm. Even in the absence of DOX inducer, there is a chance for tet-transactivators to translocate into the nucleus and activate tet-responsive promoter.
Our data indicate that this gene expression system could possibly be used to accommodate different targeted genes using different tissuespecific promoters for the delivery of a therapeutic product to a selective cell type with a timeand level-controllable capacity. The inducible transactivator (tet/VP1 6) can be replaced by others, such as GAL4 system (20) , and the MBP promoter can be substituted by other cell-specific promoters, such as an astrocyte-specific promoter glial fibrillary acidic protein (GFAP) or a neuron-specific promoter [e.g. neurofilament (21) ]. The GFP gene can be exchanged with platelet-derived growth factor (PDGF) or other neurotrophic factors, receptors, or genes of interest. A transgenic mouse model using this inducible expression construct is currently being characterized using thioredoxin peroxidase (22) as the reporter gene with an SV40 viral promoter to control the expression of rTetR/VP16.
A system that facilitates expression of a transgene in a spatial, temporal, and quantitative fashion has enormous applications in developmental biology and human gene therapy. From the human genome project, DNA sequences of an estimated 70,000 to 100,000 genes will be made available in the next few years. Our gene expression system could be an ideal tool to study the function of a selective gene when it is expressed in a cell-specific, time-and level-controllable manner. The features of this gene expression system are especially useful for studying the developmental role of a particular gene. For example, if the gene product is toxic or lethal when expressing during early embryonic development, then no live animal would be obtained (23) . The inducible expression of a transgene model is very useful in such a situation to avoid potential compensatory developments, defects, or even embryonic mortality. The animals would be normal until the inducer is administered to activate expression of the toxic or lethal gene. Human gene therapy often requires that a specific gene product be expressed in a specific tissue at a time and level determined as optimal by clinical studies. Our gene expression system is ideal for clinical testing in a therapeutical gene approach for specific monogenetic disorders. However, several barriers need to be overcome, such as long-term gene delivery and stable expression, a major goal of current research in this field.
